Amniotics

Report for the Second Quarter 2023



Amniotics – a unique biopharma company

- Amniotics cell therapy medicinal products are based on mesenchymal stem cells (MSC) from amniotic fluid. Amniotic stem cells are neonatal, meaning they are better and more potent than adult MSCs.
- Amniotics uses its own, patented CE-marked medical device, to collect amniotic fluid.
- Unique platform technology - the company's own marker technology makes it possible to identify and select the type of cell to be used for the treatment of specific tissues, such as the lung, skin, kidney or brain.
- GMP plant - The company's production of stem cells followed by fil and pack product in vials takes place in the company's own GMP production facility in Lund. This ensures accessibility and flexibility.

Positive topline study results and key patent approved

April - June in brief

- Total revenues: SEK 0 (0).
- Operating profit (EBITDA): SEK -6.0 (-10.2) million.
- Result for the period: SEK -6.5 (-10.7) million.
- Earnings per share: SEK -0.03 (-1.11).
- Cash flow for the quarter: SEK -34,5 (-3.6) million.
- Cash and cash equivalents at the end of the reporting period: SEK 5.8 (29.1) million.
- Equity/assets ratio as per the end of the reporting period: 34 (65) %.
- The Annual General Meeting held on 22 May 2023, re-elected Marcus Larsson, Christopher Bravery, Fredrik Tiberg, Ingrid Atteryd Heiman and Peter Buhl Jensen as board members. Peter Buhl Jensen was re-elected to serve as chairman of the board.
- As previously communicated, the company has during this quarter, paid out 25,3 MSEK of the EU-Pathfinder grant to the other consortium participants.
- Amniotics were able to present that the primary endpoint for the PulmoStem Phase I study was achieved, i.e., 100% survival and that no predefined complications occurred.
- In June, the outcome of the warrant program TO2 was announced, where it was gratifying that the coverage ratio was over 90%.
- The company was also granted a key patent in the EU for the company's technology platform, including PulmoStem, which is valid until at least 2040.
- Promising data on our product candidate CogniStem was presented in June at an international stem cell symposium.

Amniotics

Report for the Second Quarter 2023



Amniotics – a unique biopharma company

● Amniotics cell therapy medicinal products are based on mesenchymal stem cells (MSC) from amniotic fluid. Amniotic stem cells are neonatal, meaning they are better and more potent than adult MSCs.
● Amniotics uses its own, patented CE-marked medical device, to collect amniotic fluid.
● Unique platform technology - the company's own marker technology makes it possible to identify and select the type of cell to be used for the treatment of specific tissues, such as the lung, skin, kidney or brain.
● GMP plant - The company's production of stem cells followed by fil and pack product in vials takes place in the company's own GMP production facility in Lund. This ensures accessibility and flexibility.

January - June in brief

- Total revenues: SEK 0 (0).
- Operating profit (EBITDA): SEK -16.5 (-20.7) million.
- Result for the period: SEK -18.1 (-21.7) million.
- Earnings per share: SEK -0.09 (-1.35).
- Cash flow for the quarter: SEK -3.2 (-14.8) million.
- Amniotics carried out a rights issue that provided the company with SEK 25.3 million before issue costs and set-off and repayment of outstanding bridge loans. Outstanding loans after set-off and repayment amount to SEK 4.2 million.
- Gerton Jönsson was appointed new CFO. Gerton Jönsson took office on May 2, 2023.
- Been able to present the primary endpoint for the PulmoStem Phase I study was achieved.
- In June, the outcome of the warrant program TO2 was announced, where it was gratifying that the coverage ratio was over 90%.
- As previously communicated, the company has, during this quarter, paid out 25,3 MSEK of the EU-Pathfinder grant to the other consortium participants.
- The company was also granted a key patent in the EU for the company's technology platform, including PulmoStem, which is valid until at least 2040.
- Promising data on our product candidate CogniStem was presented in June at an international stem cell symposium.

Significant events after the end of the reporting period

- In addition to existing cash, the company has a new loan commitment of SEK 5 million to finance continued development of the existing business in accordance with the business plan.
- The company has prolonged the loan to Buntel AB(former Modelio Equity AB(publ)) 4,8 MSEK.
- The Board of Directors of Amniotics resolved on August 31, 2023, subject to subsequent approval at the Extraordinary General Meeting on October 3, 2023, to carry out an issue of not more than 2,502,044,100 units, consisting of shares and warrants, with preferential rights for the company's existing shareholders. The company can receive a maximum of approximately SEK 25 million before issue costs in the rights issue. The issue is secured to 80 percent through subscription intentions, subscription undertakings and guarantee commitments. Upon full exercise of the warrants, Amniotics may receive an additional maximum of approximately SEK 25 million before issue costs.

CEO Statement

Positive topline study results and key patent approved

During the quarter, Amniotics was able to present that the primary endpoint for the PulmoStem Phase I study was achieved, i.e., 100% survival and that no predefined complications occurred. This paves the way for continued development of PulmoStem, where the focus is to improve the outcome of lung transplants. This area is of high medical interest, as the average survival after lung transplantation is only approx. 6 years. Thus, the medical need in this area of medicine, where measures to protect the organ and the patient through cell therapy seem particularly urgent. The company was also granted a key patent in the EU for the company's technology platform for neonatal cell production and use, including PulmoStem, which is valid until at least 2040. The company has continued product optimization and regulatory work ahead of continued clinical trials of PulmoStem.

In June, the outcome of the warrant program TO2 was announced, where it was gratifying that the subscription rate was over 90%. Unfortunately, the subscription price was significantly lower than previous forecasts indicated, and the company therefore urgently needs to attract new capital. The market situation has not improved compared to the previous quarter, but our hope is that our shareholders will continue to support the company. Our savings program will take full effect from October 2023, and we can continue to deliver value increase at a significantly lower cost in this new organization.

Promising data regarding our product candidate CogniStem was presented in June at an international stem cell symposium. We were able to show that these cells were selectively enriched in the brain linked to improvement of sensory functions in a model system. This is indicative that the cells pass the blood-brain barrier. The company sees this as a very promising result, which means that we will accelerate this pre-clinical research program where the target diagnoses are the degenerative brain diseases Parkinson's, Alzheimer's and ALS.

The company has also increased its focus on contract manufacturing in the company's GMP plant as a future source of revenue. As previously communicated, the company's strategy is to establish strategic partnerships to help bear development costs, especially in later stages of clinical development, and this work continues.

Lund, August 2023
Marcus Larsson

Amniotics in brief

Amniotics develops and manufactures stem cell therapies in the company's own GMP certified facility

Amniotics origin

Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue specific neonatal mesenchymal stem cells (MSC). Researchers and founders of the company, pediatrician Marcus Larsson, obstetrician Andreas Herbst and stem cell specialist Niels-Bjarne Woods discovered a new type of stem cells in amniotic fluid that has properties for applications in regenerative medicine.

Amniotics is a biopharma company that develops cell therapy drugs based on mesenchymal stem cells (MSC) from amniotic fluid. These MSC are neonatal, which means that they are better than MSC from adult individuals in several important aspects (e.g. virus burden, growth capacity). As of now, it is Amniotics assessment that the company is the only currently active company that can produce neonatal tissue specific MSC from amniotic fluid for a number of indications. The amniotic fluid is collected during planned caesarean sections using Amniotics proprietary CE-marked medical device. Amniotics own marker technology is then used to identify and select stem cells for different tissue types;

- Lung (PulmoStem™)
- Brain (CogniStem™)
- Kidney (NephroStem™)
- Skin (CutiStem™)

Novel treatments for unmet needs

For a number of diseases and conditions where effective treatment is currently lacking or is insufficient, stem cells can be a potential alternative. Amniotics sees an opportunity to address this medical need by developing new effective treatment methods based on these neonatal tissue specific MSC.

Amniotics vision is to contribute to the successful treatment of human diseases by providing the very best stem cells for medical applications.



Technology

Amniotics unique technology allows for selecting the type of tissue-specific neonatal stem cells to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility.

Strategy

Amniotics strategy is to develop treatments for diseases with severe inflammatory and fibrotic components, where tissue specific stem cells are expected to have an impact on potential future life-changing treatments. The objective is to successfully conduct and complete phase I/II clinical trials. For the later stage clinical development and commercialization Amniotics intends to seek licensing partners.

Amniotics is presently producing clinical batches of lung specific MSC (PulmoStem™). With the results from Amniotics™ preclinical studies and

the characterization of the quality attributes of the cells (sterility, identity, purity, injectability Amniotics can proceed to clinical testing. All candidates are in the early development phase except PulmoStem™, which was evaluated in a clinical study during 2023 which resulted in positive Topline-data with safety and tolerability being shown. Amniotics strategy also includes being an active and attractive contract manufacturer of potent MSCs to external research programs in order to increase the utilization rate of Amniotics GMP approved manufacturing facility.

Several patented technologies and concepts

Large values lie in the scientific knowledge, the developed process and the technology built by Amniotics. The Company has a well-developed IP strategy that works broadly to protect this value and by protecting the Company's position in the market from competitors and competing technologies. The Company has three patent families attributable to the Company's MSC products intended for use in several treatments / indications. In addition, the Company has filed an additional 14 patent applications, of which 12 are in new patent families.

Cell therapy market

There are only a few approved cell therapies on the market today. However, the area is expected to grow in the coming years driven by clinical successes that are accelerating investments. GlobalData estimates that the area of regulated cell therapies will reach $ 3.1 billion by 2026. Cell therapies have the potential to change future treatments due to their therapeutic potential for a variety of diseases. The US Food and Drug Administration estimates that the approval of drugs based on cell and gene therapy will increase substantially between 2021 and 2025. The first MSC-based drug to receive European approval (Alofisel from TiGenix / Takeda) was approved by the European Medicines Agency EMA in March 2018.

Drug development with cell therapy

Amniotics focuses on the treatment of diseases where a smaller but well-defined group of patients (orphan drug designations included) has a great need for better treatment. Amniotics marker technology for identifying different populations of MSC is based on tissue-specific cell surface markers that have been identified during the research and development work by the Company. Amniotics uses the markers and marker-specific antibodies to identify and select homogeneous and high-quality stem cells for the development of disease-specific cell therapies. The use of markers and the patent-pending selection technology is one of several components that distinguish Amniotics from other stem cell companies.

Contract development and contract manufacturing of cell therapy

Amniotics other business opportunity lies within the Company's own production service. With its own GMP production facility, Amniotics has secured production of its own products and is not dependent on outsourcing to a third party. This gives Amniotics an comparative advantage as well as a control over the value chain, without the need for contracting and transferring knowhow to an external manufacturer.

Amniotics is also offering contract development and contract manufacturing of advanced therapy medicinal product (ATMPs) to the pharmaceutical industry, universities and to hospitals.

Amniotics has the capacity to work with other companies to add value through e.g.:

- Process development for ATMP at Amniotics GMP manufacturing facility in Lund
- Work with companies to help launch their products
- Assist in solving operational challenges such as capacity constraints

Amniotics Pipeline

Amniotics project portfolio is based on proprietary technology and methodology. The pipeline is made up of pulmonary indications (PulmoStem™), brain indications (CogniStem™), dermatological indications (CutiStem™) and kidney-specific indications (NephroStem™).

Amniotics lung-specific product PulmoStem™ has during 2023 been evaluated in a first clinical study in humans with the primary aim of demonstrating that the product is safe and well tolerated and these goals were met. Based on favorable experimental data in a lung transplantation model, PulmoStem development will be focused on improving outcome after lung transplantation. Amniotics other cell-specific products are still at an earlier stage and will in the coming years continue to be developed towards clinical phase. iPS technology is another opportunity at an early stage with the potential to shape a new platform and a new group of indications for Amniotics. Following Phase I/II clinical trials of PulmoStem™, Amniotics intends to seek a partner for out licensing the products / technology for the development of treatment for relevant lung diseases.

Pipeline – current prioritized areas

Platform	Candidate	Indication	Discovery	Preclinical	Phase I	Phase II / Partnering	Upcoming milestones
STEM CELLS (MSC)	PulmoStem™	**ARDS (COVID-19)**					Final report H2 2023
	PulmoStem™	**Lung Transplantation**					CTA, H2 2023
NK-cells (iPSC)	AMNI-NK003	**Oncology**					GMP Optimization, H1 2024

Amniotics additional platform candidates

Platform	Candidate	Indication	Discovery	Preclinical	Phase I	Phase II / partnering
STEM CELLS (MSC)	PulmoStem™	Idiopathic pulmonary fibrosis (IPF)				
	CogniStem™	Neurodegenerative disease. Parkinson's, Alzheimer, ALS				
	NephroStem™	Acute kidney injury Transplantation				
EVs	CutiStem™	Epidermolysis Bullosa Burns/wound healing (Skin)				

ARDS - Acute Respiratory Distress Syndrome
iPSC - induced pluripotent stem cell
Evs - Extracellular vesicles
CTA – Clinical Trial Application to authorities to start the study

Completed
Ongoing
Planned

Financial performance in summary

	Quarter 2		H1		Full year
(SEK 000)	2023	2022	2023	2022	Year
Net sales	0	0	0	0	0
Operating result	-6,600	-10,604	-17,579	-21,616	-46,693
Cash flow from operating activities	-39,111	-12,705	-16,945	-23,499	-46,185
Cash position	5,831	29,135	5,831	29,135	9,104
Equity/assets ratio %	34	65	34	65	5
Earnings per share (SEK)	-0,03	-0,66	-0,09	-1,35	-2,99

Financial overview

Comprehensive result
Comprehensive result for the quarter was SEK -6,8 (-10,7) million, which corresponds to an improvement of SEK 3,9 million. Earnings per share, based on the number of shares at the end of the quarter, totaled SEK -0.03 (-0,66).

In the half year, the comprehensive result was SEK -18,4 (-21,7) million, which corresponds to an improvement of SEK 3,3 million. Earnings per share, based on number of shares at end of the period, totaled SEK -0,09 (-1.35).

Expenses
Operating expenses for the second quarter totaled SEK 8,7 (10,7) million, a decrease of SEK 2,0 million. Other external costs decreased by SEK 2,6 million and amounted to SEK 3,9 (6,5) million. The reduction is mainly because in 2022, the company had costs of 2 million for clinical studies. Personnel costs amounted to SEK 3.6 (3,7) million, a decrease of SEK 0.1 million. Financial costs increased by SEK 104 thousand, due to interest on an already taken short-term loan, and amounted to SEK 191 (77) thousand.

Operating expenses for the half year amounted to SEK 20,7 (21,8) million, a decrease of SEK 1,1 million. Other external costs amounted to SEK 7,8 (12,3) million, a decrease of SEK 4,5 million. A large part of the reduction is due to the costs for clinical studies. Personnel costs increased by SEK 1,8 million because of severance pay compared to the previous year and amounted to SEK 10,2 (8,4) million.

Investments
The company's net capital expenditure during the quarter amounted to SEK 0,5 (0,7) million, including SEK 0,0 (0,4) million attributable to property, plant, and equipment, and SEK 0,5 (0,3) million relating to investments in intangible assets.

The company's net capital expenditure during the half year amounted to SEK 1,4 (1) million, including SEK 0,7 (0,4) million attributable to property, plant, and equipment, and SEK 0,7 (0,6) million relating to investments in intangible assets.

Cash flow and financial position
Total shareholders' equity at end of the period was SEK 9,0 (27,8) million after taking the result for the quarter into account. Equity per share (basic and diluted) based on the number of outstanding shares at the end of the period was SEK 0,04 (1 733). The company's equity ratio at the end of the quarter was 34 (65) percent.

Cash and cash equivalents at the end of the period amounted to SEK 5,8 (29,1) million. The company has announced that it intends to carry out a rights issue of SEK 25 million during the third quarter of 2023, which is secured to 80 percent. In connection with the upcoming rights issue, Amniotics has renegotiated and extended outstanding loans to Buntel AB (which has taken over previous loans from Modelio Equity AB) of approximately SEK 4.8 million. For any part of the rights issue that is subscribed for in excess of the secured ratio (i.e. 80 per cent), at least half of the volume subscribed for in excess of the secured level (up to the entire debt from the loan) shall be repaid and be received by Buntel AB after completion of the rights issue. The remaining part of the loan shall be repaid earlier of the following occasions: one (1) business day after the shares issued upon exercise of the warrants series TO 3 issued in the rights issue have been registered at the Swedish Companies Registration Office, and (2) on March 31, 2024.

In addition, the company has raised loans from LSCS Invest AB and Deflexum AB of SEK 5 million to finance continued development of the existing business according to the business plan.

Cash flow for the quarter was SEK -34,5 (-3,6) million. Cash flow from financing activities totaled SEK 0 (-0,1) million. As previously communicated, the company has, during this quarter, paid out 25,3 MSEK of the EU-Pathfinder grant to the other consortium participants.

Cash flow for the half year amounted to SEK -3,2 (-14,8) million. Cash flow from financing activities during the period amounted to SEK -5,8 (9,7) million.

Organization
The number of employees at the end of the reporting period was 11, this a decrease of 9 people compared with previous year when it was 20 employees.

Share capital
Share capital at the end of the quarter was SEK 11 277 784 and the total number of shares was 208 503 675 with a par value of SEK 0.05409.

Other information

Risks factors
A pharmaceutical development company such as Amniotics is exposed to significant operational and financial risk. Amniotics operational and external risks mainly consist of risks related to research and development, clinical trials, and dependence on key employees. Many factors can have a negative impact on the probability of commercial success. The risks to which the Company is exposed in its current phase and the risk that the necessary financing cannot be secured. During the quarter no significant changes with respect to these risks or uncertainty factors have arisen.

Auditor's review
This report has not been reviewed by the Company's auditor.

Liquidity and financing
The company's cash and cash equivalents at the end of the quarter amounted to SEK 5,8 (29,1) million.

The company has announced that it intends to carry out a rights issue of SEK 25 million during the third quarter of 2023, which is secured to 80 percent. In connection with the upcoming rights issue, Amniotics has renegotiated and extended outstanding loans to Buntel AB (which has taken over earlier loans from Modelio Equity AB) of approximately SEK 4.8 million. For any part of the rights issue that is subscribed for in excess of the secured ratio (i.e. 80 percent), at least half of the volume subscribed for in addition to the secured level (up to the entire debt from the loan) shall be repaid and be received by Buntel AB after completion of the rights issue. The remaining part of the loan shall be repaid earlier of the following occasions: one (1) business day after the shares issued upon exercise of the warrants series TO 3 issued in the rights issue have been registered at the Swedish Companies Registration Office, and (2) on March 31, 2024.

In addition, the company has raised loans from LSCS Invest AB and Deflexum AB of SEK 5 million to finance continued development of the existing business according to the business plan.

The board and company management are assessing alternatives to secure the company's long-term capital requirement on an ongoing basis.

The share
The number of shares at the end of the period amount to 208 503 675. All shares are of the same class and have the same voting rights. Amniotics shares are traded on Nasdaq First North Growth Market and traded under the ticker symbol AMNI and ISIN code E0015961016.

First North is Nasdaq's European emerging market intended for small, growing businesses, with a less extensive rulebook than the main market.

Legal disclaimer
This report contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, like research and development work in the biotech field, associated with risk and uncertainty. Considering this, actual outcomes may differ substantially from what is described in this report.

Future reporting dates

- Interim Report Q3, Nov 27th, 2023

The financial reports will be made available on Amniotics website:

https://www.amniotics.com/investors/financial-reports/

For further information, please contact
Marcus Larsson, CEO
Phone: +46 (0)705 67 87 57
Email: ml@amniotics.com

Gerton Jönsson, CFO
Phone: +46 (0)724 02 31 61
Email: gj@amniotics.com

Certification by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Company's business activities, financial position and results of operations and describes significant risks and uncertainties facing the Company.

Lund, August 31th, 2023

Amniotics AB (publ)

Marcus Larsson CEO	Peter Buhl Jensen *Chairman*	Ingrid Atteryd Heiman *Board member*
Christopher Bravery *Board member*	Fredrik Tiberg *Board member*	

Financial Statements

Income statement in Summary

	Quarter 2		H1		Full-Year
SEK 000	**2023**	**2022**	**2023**	**2022**	**2022**
Other operating income	1 957	50	2 273	86	553
Operating income	1 957	50	2 273	86	553
Operating expenses					
Other external costs	-3 900	-6 463	-7 799	-12,313	-26 622
Personnel costs	-3 558	-3 696	-10 213	-8,404	-18 507
Other operating costs	-597	-48	-852	-108	-324
Operating result before depreciation and amortization (EBITDA)	-6 097	-10 157	-16 590	-20,739	-44 900
Depreciation of tangible and intangible assets	-502	-448	-988	-877	-1 793
Operating result (EBIT)	-6 600	-10 605	-17 579	-21,616	-46 693
Net financial items	-191	-77	-803	-77	-1 353
Result after financial items	-6 792	-10 682	-18 382	-21,693	-48 046
Taxes	0	0	0	0	0
Result for the period	-6 792	-10 682	-18 382	-21,693	-48 046

	Quarter 2		H1		Full-Year
	2023	**2022**	**2023**	**2022**	**2022**
Earnings per share (SEK)*	-0,03	-0,66	-0,09	-1,35	-2,99
Earnings per weighted average number of share(SEK)**	-0,06	-0,66	-0,25	-1,35	-2,99
Earnings per shares before dilution of shares***	-0,06	-0,66	-1,14	-1,35	-2,99
Earnings per shares before dilution of shares****	-0,42	-0,66	-1,14	-1,35	-2,99
Number of shares					
Weighted average for the period after dilution of shares	119 289 033	16 066 033	73 252 851	16 066 033	16 066 033
Weighted average for the period before dilution of shares	16 066 033	16 066 033	16 066 033	16 066 033	16 066 033
Number of shares at start of period	117 284 210	16 066 033	16 066 033	16 066 033	16 066 033
Number of shares at end of period	208 503 675	16 066 033	208 503 675	16 066 033	16 066 033

** Based on number of shares at end of period*

***Based on weighted average number of shares for the period*

****Based on number of shares at start of period*

*****Based on number of shares per 23-01-01*

Balance sheet in Summary

SEK 000	June 2023	June 2022	Dec. 31 2022
Assets			
Fixed assets			
Intangible assets	7 263	5 004	6 552
Equipment and installations	6 484	7 250	6 798
Total fixed assets	**13 747**	**12 254**	**13 350**
Current assets			
Other receivables	6 909	1 740	6 464
Cash and bank balances	5 831	29 135	9 104
Total current assets	**12 740**	**30 875**	**15 568**
Total assets	**26 487**	**43 129**	**28 918**
Shareholders' Equity and Liabilities			
Shareholders' equity			
Restricted equity			
Share capital	11 278	869	869
Reserve for development expenses	167	167	167
Non- restricted equity			
Share premium reserve	76 307	0	60 793
Accumulated loss including profit/loss for the period	-78 728	26 800	-60 346
Total shareholders' equity	**9 024**	**27 836**	**1 484**
Liabilities			
Liabilities to credit institutions, long-term	0	0	0
Current liabilities	17 463	15 293	27 434
Total liabilities	**17 463**	**15 293**	**27 434**
Total shareholders' equity and liabilities	26 487	43 129	28 918

Financial key ratios

Shareholders' equity per share, SEK	1,733	1,733	0,09
Equity/assets ratio %	65	65	5

* Based on the number of shares at the end of the period.

Changes in equity

	H1		Full Year
SEK 000	2023	2022	2022
Opening balance	1 484	49,530	49 350
Issue of shares	25 922	0	0
Loss for the period	-18 382	-21,693	-48 046
Equity at end of period	**9 024**	**27,836**	**1 484**

Cash Flow statement

	Quarter 1		H1		Full Year
SEK 000	2023	2022	2023	2022	2022
Operating result	-6,600	-10,604	-17,579	-21,616	-46 693
Amortization and depreciation	502	448	988	877	1 793
Other, including non-cash items	-233	-20	-750	-54	-1 455
Cash flow from operating activities before change in working capital	-6,331	-10,176	-17,341	-20,793	-46 355
Change in working capital	-32,780	-2,529	396	-2,706	170
Cash flow from operating activities	-39,111	-12,705	-16,945	-23,499	-46 185
Investing activities	-593	-729	-1,385	-1,015	-3 027
Cash flow after investing activities	-39,704	-13,434	-18,330	-24,514	-49 212
Financing activities	0	9,801	-5,851	9,668	14 335
Rights issue	5,229	0	20,908		0
Change in cash and cash equivalents	**-34,475**	**-3,633**	**-3,273**	**-14,846**	**-34 876**
Cash and cash equivalents at the beginning of the period	40,306	32,768	9,104	43,981	43 981
Cash and cash equivalents at the end of the period	**5,831**	**29,135**	**5,831**	**29,135**	**9 104**

Glossary

ATMP: Advanced Therapy Medicinal Products (ATMPs) are a new type of medicine that are based on cells, tissues, and genes. ATMPs are a type of biological medicine, and they are given for the purpose of treating or preventing diseases in humans. They can restore, correct, or modify physiological functions through their pharmacological, immunological, or metabolic actions.

GMP: Good manufacturing practice is a system or structure for ensuring that products are consistently produced and controlled according to quality standards. Thereby minimizing the risks involved in pharmaceutical production.

MSC: Mesenchymal stem cells are multipotent stem cells that are present in multiple tissues. They have a range of biological activities which have the potential to treat a range of human diseases.

Stem cells: Stem cells are a collective name for different types of cells with the ability for self-renewal as well as development and maturation into more specialized cells.

PDG: Primary graft dysfunction is a type of severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality.

ARDS: Acute respiratory distress syndrome. Several conditions can trigger an inflammation in the lungs that makes it difficult for the body to oxygenate itself. Shortness of breath is a serious condition caused by inflammation. The incidence has increased markedly in connection with the covid-19 pandemic.

Amniotics AB (publ)
Medicon Village,
Scheelevägen 2
SE-223 63 Lund
Sweden

www.amniotics.com